Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Portfolio Pulse from
Ligand Pharmaceuticals has led a $75 million royalty financing for Castle Creek Biosciences to fund a Phase 3 clinical trial for D-Fi, a treatment for dystrophic epidermolysis bullosa. Ligand invested $50 million, with co-investors contributing $25 million, in exchange for royalties.
February 25, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ligand Pharmaceuticals has invested $50 million in a royalty financing agreement with Castle Creek Biosciences to support a Phase 3 clinical trial for D-Fi, potentially boosting Ligand's future revenue through royalties.
Ligand's significant investment in the Phase 3 trial of D-Fi could lead to future royalty revenues if the trial is successful, positively impacting Ligand's financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90